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Hereditary non-polyposiscolon cancer (HNPCC) isa com-
mon hereditary disease characterized by a predisposition to
an early onset of colorectal cancer. The majority of the
HNPCC families carry germline mutations of either hM SH2
or hM LH1 genes, whereas germline mutations of hPM S1 and
hPM S2 genes have rarely been observed. Almost all of the
germline mutations reported so far concern typical HNPCC
families. However, there are families that display aggrega-
tions of colon cancer even though they do not fulfil all
HNPCC criteria (incomplete HNPCC families) as well as
sporadic cases of early onset colon cancers that could be
related to germline mutations of these genes. Therefore, we
screened germline mutations of hM SH2 and hM LH1 genes in
3 groupsof patientsfrom France and Turkey: typical HNPCC
(n 5 3), incomplete HNPCC (n 5 9) and young patientswith-
out apparent familial history (n 5 7). By in vitro synthesis of
protein assay, heteroduplex analysis and direct genomic
sequencing, we identified 1 family with hM SH2 mutation and
5 families with hM LH1 mutations. Two of the 3 HNPCC
families(66%) displayed hM LH1 germline mutations. Interest-
ingly, 4 of 9 families with incomplete HNPCC (44%) also
displayed mutations of hM SH2 or hM LH1 genes. In contrast,
no germline mutation of these genes was found in 7 young
patients. Our resultsshow that germline mutationsof hM SH2
and hM LH1 genes contribute to a significant fraction of
familial predisposition to colon cancer cases that do not fulfil
all diagnostic criteria of HNPCC. Int. J. Cancer 73:831–836,
1997.
r 1997 Wiley-Liss, Inc.
Hereditary non-polyposis colon cancer (HNPCC) is an autoso-
mal dominant inherited disease characterized by a predisposition to
an early onset of colorectal cancer. HNPCC is estimated to account
for 5–10% of all colon cancer cases in Western populations. The
families with aggregation of colorectal cancer are identified as
HNPCC families if they fulfil the following criteria defined by the
International Collaborative Group on HNPCC (Amsterdam Crite-
ria): 1) 3 or more relatives with histologically verified colorectal
cancer, one of whom is a first-degree relative of the other 2; 2)
colorectal cancer affecting at least 2 generations; and 3) one or
more colorectal cancer cases diagnosed before age 50 (Lynch et al.,
1993). In addition to colorectal cancer, certain extra-colonic
malignancies are characteristic of HNPCC. Carcinomas of the
endometrium, ovary, small intestine, biliary tract, ureter, renal
pelvis, stomach and pancreas are present at an increased frequency
in HNPCC families (Lynch et al., 1993). Germline mutations of 4
human genes involved in DNA mismatch repair (hMSH2, hMLH1,
hPMS1 and hPMS2) have been associated with HNPCC. Mutations
of these genes have been found in up to 70% of the HNPCC
kindreds, with mutations in hMSH2 and hMLH1 accounting for the
majority of the cases (Liu et al., 1996). Germline mutations of
hMSH2 and hMLH1 have also been found in sporadic cases
developing colon cancer before 35 years of age (Liu et al., 1995).
However, little is known about the etiology of familial aggregations
of colorectal cancers not fulfilling all HNPCC diagnostic criteria.
Such cancers could represent familial predisposition to colon
cancer or they could represent aggregation of sporadic cancers
independent of germline mutations.
The mutational spectrum of these genes appears to be diverse, in
both the localization and the nature of the mutations. Although
more than 60% of the described mutations are nonsense or
frameshift mutations that generate a premature stop codon, in
certain populations the missense mutations are frequent or even
predominant (Han et al., 1995; Tannergard et al., 1995). Loss of
heterozygosity or somatic mutations of hMLH1 and hMSH2 in
tumors have been described, suggesting that these genes behave as
tumor suppressor genes that require 2 hits to inactivate their
function (Hemminki et al., 1994).
Our aim was to investigate germline mutations of hMLH1 and
hMSH2 genes in 3 categories of colon cancer: typical HNPCC
families, familial aggregation of colon cancer not fulfilling HNPCC
criteria (incomplete HNPCC) and early onset sporadic colon
cancers. We used 3 complementary techniques for mutation
screening: in vitro synthesis of protein (IVSP) from cDNA,
heteroduplex analysis and direct sequencing of all exons as well as
intron-exon junction regions. One mutation in the hMSH2 gene and
5 mutations in the hMLH1 gene have been identified, with 1
affecting the initiation codon for protein translation.
MATERIAL AND METHODS
Family and patients selection
French families and patients were collected from genetic consul-
tations at the Centre Léon Bérard and Hôpital Edouard Herriot.
Three groups of families or patients were selected: 1 family with
typical HNPCC syndrome (which fulfils the Amsterdam Criteria),
9 families with incomplete HNPCC syndrome for which one of the
Amsterdam Criteria items was missing and 7 patients who devel-
oped colon cancer before 50 years of age without apparent familial
history of colon cancer (Table I). Two other typical HNPCC
families were collected from Turkey. One family (TF1) was from
Southern Turkey studied at the Medical School of Akdeniz
University. The other family (TF2) was from Istanbul.
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In vitro synthesis of protein assay
mRNA was obtained from the EBV-transformed lymphoblastoid
cell lines of patients using the QuickPrep Micro mRNA purification
kit (Pharmacia, Uppsala, Sweden). RT-PCR of hMLH1 and hMSH2
was performed using primers and PCR conditions as described
(Papadopoulos et al., 1994; Liu et al., 1994). RT-PCR products
were then used in coupled in vitro transcription-translation reac-
tions using TNT Coupled Reticulocyte Lysate Systems (Promega,
Madison, WI) with 40 µCi of 35S-methionine for each reaction. The
resulting polypeptides were analyzed on a 7.5–12.5% SDS-PAGE
gel and visualized by autoradiography.
Heteroduplex analysis and direct sequencing of genomic DNA
DNA was extracted from peripheral blood, or cell lines or
formalin-fixed paraffin-embedded sections of tumor tissues by
proteinase K digestion and phenol purification. Each exon and
exon-intron junction region of hMLH1 and hMSH2 genes was
amplified with primers and conditions previously described (Kolod-
ner et al., 1994; 1995). For heteroduplex analysis, each PCR was
performed with the addition of 0.05 µl 33P-dATP. Five microliters
of PCR reaction was then electrophoresed through a 0.6 3 MDE
matrix (FMC BioProducts, Rockland, ME) and visualized by
autoradiography. For nucleic acid sequencing, the PCR products



















TF15 A C (40) B: C (?) C (13) hMLH1 551 AAC= ACC (Asn= Thr)
F: C (?) C (50)
S: C (45) C (45)
B: C (60) C (?)
N (7)
C (60)
TF2 A C (40) M: C (42) hMLH1 295 AGT= ACT (Ser= Thr)
B: C (42)
FF2 B C (35) St: CUS (52) C (30) hMLH1 297 GAA= TAA (Glu= stop)
F: C? (35) CD (60)
FF3 B C (37)/E (38) M: H (53) C (46)
H (40)
E (76)
FF4 B C (72) F: C (57)
D: B (48)





FF 6 B C (31) F: R (53) C (70)
M (64)
FF 7 B C (45) S: C (32) Br (?) hMLH1 182 AGG= GGG (Arg= Gly)
B: CUS (36) CD (?)
M: CUS (42) S (39)
H (?)
FF 8 B R (45)/C (54)/Cae (63) B: C (44)
B: C (54)
CD (80) hMSH2 Splice donor
of exon 5





FF 9 B C (39) S: C (38) P (58)
F: Leu (82) CUS (40)
FF 10 B C (45) S: C (34) E (43)/C (65) hMLH1 1 ATG= AGG (Met=)
FF 11 C C (46) F: L (55) Lym (53)
L (?)
FF 12 C C (32) Leu (?)
FF 13 C C (41) M: CUS (45)
FF 14 C C (23) F: HN (37)
FF 15 C C (33)/O (35) F: L (60) M (64)
Leu (17)
FF 16 C R (43) S: O (34)
M: B (69)
FF 17 C R (46) F: L (65) HN (6)
1A, classical HNPCC families; B, atypical HNPCC families; C, young patients without family history.–2For the first-degree relatives: M,
mother; F, father; B, brother; S, sister; St, twin sister; So, son; D, daughter.–3For cancer spectrum: B, breast cancer; Br, brain tumor; C, colon
cancer; Cae, cancer of caecum; CD, cancer of digestive system; CUS, cancer of unknown site; E, endometrum carcinoma; H, hepatocarcinoma;
HN, head and neck cancer; L, lung cancer; Leu, leukemia; Lym, lymphoma; M, myeloma; N, neuroblastoma; O, ovarian cancer; P, cancer of
pancreas; R, cancer of rectum.–4Between 5 and 65.–5FF, French families; TF, Turkish families.
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were purified through microSpin columns of Sephacryl S-300
(Pharmacia) and then sequenced on both strands using the PRISM
Dye Terminator sequencing Ready Reaction kit (Applied Biosys-
tems, Foster City, CA) with an Applied Biosystem model ABI
373A automated sequencer. The same primers as for PCR amplifi-
cation were used for the sequencing reaction of each exon.
Analysis of in vivo expression of hMLH1 protein
Cellular lysate from lymphoblastoid cell lines was prepared as
described elsewhere (Laffe et al., 1995). One hundred micrograms
of protein were separated on a 7.5–12.5% acrylamide gel. hMLH1
protein was detected by polyclonal antibodies directed against the
amino-terminal region (amino acids 2–21, catalogue number sc-58,
at a dilution of 1:500) and the carboxy-terminal region (amino
acids 737–756, catalogue number sc-582 at 1:2,000 dilution) of
hMLH1 (Santa Cruz Biotechnology, Santa Cruz, CA). A chemilu-
minescence detection system (ECL, Amersham, Aylesbury, UK)
was used to visualize the specific products.
RESULTS
We combined 3 technical approaches: IVSP, heteroduplex analy-
sis and genomic DNA sequencing to search for germline mutations
in hMLH1 and hMSH2 genes, to detect both nonsense or frameshift
mutations and missense mutations. Although it is time consuming,
direct genomic DNA sequencing remains the most sensitive
method for mutation detection. A set of 19 patients was analyzed: 3
from typical HNPCC families, 9 from incomplete HNPCC families
and 7 young patients diagnosed before the age of 50 (Table I).
Heteroduplex analysis and direct genomic DNA sequencing were
performed for all patients, while IVSP was carried out for all but
the patient from TF1, whose lymphoblastoid cell line was not
available. One germline mutation in the hMSH2 gene and 5
germline mutations in the hMLH1 gene were detected (Table I). All
mutations were verified by repeated PCR reactions performed on
independent DNA or RNA preparations.
Two missense mutations of the hMLH1 gene were identified in
Turkish families out of 3 typical HNPCC families analyzed (Table
I). The patient from family TF1 had an A = C transversion at
codon 551 of exon 14, leading to a substitution of Asn by Thr. TF1
is a large kindred (Fig. 1), with 11 members through 3 generations
affected by colon cancer before 60 years of age. This A = C
transversion was found in 2 other affected members. In family TF2,
the missense mutation was a G= C transversion at codon 295 of
exon 10, which changes amino acid Ser to Thr. As for the previous
case, this mutation was present in another affected family member.
In addition, a homozygous G = C mutation was revealed in the
tumors of these 2 patients, suggesting a somatic loss of wild-type
allele. To test whether these 551 A = C, and 295 G = C
transversions were true mutations or polymorphisms, we analyzed
50 additional unrelated individuals from the Turkish population.
No such transversions were found in any of them.
FIGURE 2 – In vitro synthesis protein assay. The RT-PCR products
from the N-part (fragment A) of hMLH1 gene (codon 1-394) were
transcribed and translated in vitro (see Material and Methods) and
separated on a 10% SDS-acrylamide gel. The polypeptides in lanes 1–4
were obtained from different cDNA preparations of the patient carrying
a nonsense mutation at codon 297. A truncated protein of about 35 kDa
is indicated by an arrow. The product in lane 5 was obtained from a
healthy individual and the product on lane 6 from a patient with hMSH2
mutation (supplied by B. Bressac de Paillerets, Institut Gustave
Roussy, Paris, France). The normal size of the polypeptide from
fragment A is 48 kDa.
FIGURE 1 – Pedigree of family TF1. h, male (age); s, female (age); j and d, individuals affected by colorectal cancer (age at diagnosis); m/w,
heterozygote for mutation of codon 551: AAC=ACC (Asn= Thr); w/w, wild type on both alleles.
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Among 9 French families with incomplete HNPCC, we detected
1 mutation of the hMHS2 gene and 3 mutations of the hMLH1 gene
(Table I). The hMSH2 gene mutation was located at the splice
donor at the 38 end of exon 5, resulting in an in-frame deletion of
this exon. This mutation was found in an incomplete family (FF8)
with 3 colon cancer cases and 1 endometrial case among 5 brothers
and sisters. The mutation carrier developed a multifocal cancer, a
rectal cancer at the age of 45, a primary cancer in the distal colon at
54 and a primary cancer in the caecum at 63.
Among the 3 hMLH1 mutations detected in French families, 1
was a missense mutation, observed in a family with 2 sisters who
developed cancers in the proximal colon ages 45 and 32, respec-
tively (FF7). This mutation was an A= G transition at codon 182
of exon 6, resulting in an Arg= Gly change. The same alteration
was identified in the 2 patients of the family but was not observed
in 48 additional unrelated individuals from the French population.
The second hMLH1 mutation was a G=T substitution producing a
stop codon at codon 297 of exon 11 (FF2). A truncated protein
synthesized from a mutated allele was revealed by IVSP (Fig. 2)
with different preparations of cDNA. This mutation was identified
in a patient with colon cancer (site undefined) at the age of 35. Her
father was suspected to be affected by a colon cancer, but this was
not confirmed. Her twin sister had died from a generalized cancer at
52. The son of his sister (the nephew of the patient) developed a
distal colon cancer at age 30. The third hMLH1 mutation was
identified in a patient with proximal colon cancer at age 45 (FF10).
Her sister was affected by colon cancer (site undefined) at age 34.
Their maternal aunt developed an endometrial cancer at age 43 and
a colon cancer at age 65. The mutation was a T= G transversion
affecting the initiation codon (Fig. 3A), abolishing the signal for
initiating protein translation. Consequently, 2 fates for the mutant
allele were possible: either this transcript was not translated at all,
or it used another ATG as a start codon to initiate translation. The
second hypothesis would result in a truncated protein missing the
amino-terminal part. Sequencing of cDNA demonstrated that the
mutant allele was transcribed (Fig. 3A). By IVSP, we detected a
faint band of about 3 kDa smaller than the wild-type one (Fig. 3B).
This suggested that the next in-frame codon ATG, located 100 bp
downstream, was used as a initiation codon to synthesize the
protein in this in vitro system. This mutation was also detected in
another affected member of the family who developed an endome-
trial cancer at age 43 and a colon cancer at age 65. To determine
whether the mutant alleles were expressed in vivo, we studied
hMLH1 protein by Western blot. As shown in Figure 4, only
full-length proteins were detected in all cell lines from both the
controls and the patients carrying nonsense or missense mutations.
No predicted abnormal, short polypeptides resulting from nonsense
mutations were found (Fig. 4). This indicates that the truncated
proteins were not translated or were rapidly degraded after
translation in normal cells. Besides the specific hMLH1 protein,
other bands of different sizes were revealed, which might be due to
FIGURE 3 – Sequencing and IVSP analysis of mutation at the initiation codon of the hMLH1 gene. (A) A portion of the chromatogram of
antisense sequencing of exon 1. a, genomic DNA sequence of a healthy individual; b, genomic DNA sequence of the patient; c, cDNA sequence of
a healthy individual; d, cDNA sequence of the patient. A heterozygous T= G mutation in both genomic DNA and cDNA is indicated (arrow). (B)
RT-PCR products of fragment A (codon 1-394) were transcribed, translated in vitro (see Material and Methods) and separated on a 7.5%
acrylamide gel. A truncated protein was shown in lane A (synthesized from the RT-PCR product of the patient), indicated by an arrow. Products in
lanes B–D were obtained from the patients without the hMLH1 mutation. The normal size of the polypeptide from fragment A is 48 kDa.
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alternative transcriptions (Charbonnier et al., 1995) or non-specific
cross-reactions with unknown proteins.
DISCUSSION
Six mutations of hMLH1 and hMSH2 genes were found in
typical and incomplete HNPCC families. In contrast, no mutation
was detected in 7 young patients without a family history,
suggesting that neo-mutations of these genes are likely to be
infrequent. None of the 5 mutations in the hMLH1 gene has been
previously described, whereas the deletion of exon 5 in hMSH2
gene resulting from the mutation at the splice donor site was
reported in several families of different geographic origins (Liu et
al., 1995, 1996). This suggests that exon 5 of hMSH2 is either a
functionally important site or is structurally vulnerable. Among the
5 hMLH1 germline mutations, 2 were nonsense mutations with one
affecting the initiation codon of the gene. A mutation at the
initiation codon was reported in the a globin gene, causing
a-thalassemia (Pirastu et al., 1984). We have thus detected a
mutation affecting the initiation codon in a cancer predisposition
gene. The mutant allele of hMLH1 was transcribed and the
truncated protein was synthesized in vitro probably using the next
in-frame ATG as the initiation codon. However, this truncated
protein was probably unstable since only small levels of protein
were detected by IVSP. In vivo, the truncated protein was not
detectable. However, the possibility that the abnormal product
co-migrated with the product from the wild-type allele cannot be
excluded. Similarly, we did not detect the truncated protein in
normal cells of the patient carrying the nonsense mutation at codon
297 (family FF2). Consistent with our finding, predicted aberrant
proteins resulting from germline mutations of other predisposition
genes, such as hMSH2 and APC, are also undetectable by Western
blot (Smith et al., 1993; Leach et al., 1996). As shown by
immunoblot analysis, levels of wild-type hMLH1 protein were similar
in patients carrying nonsense mutations and in control individuals.
Although Western blot is a semi-quantitative method, this observation
might suggest the existence of functional compensation to the wild-type
allele in the normal cells of the patients.
Missense mutations of hMLH1 reported in our study involve
codons 182, 295 and 551 of the gene. Although we cannot definitely
exclude the possibility of rare polymorphisms, several observations
strongly suggest that these mutations are involved in the familial
predisposition to colon cancer: 1) mutations co-segregate with the
disease; 2) no polymorphism at codons 182, 295 and 551 have ever been
reported, and these mutations were not present in unrelated individuals
of the same population; 3) codons 182 and 551 are evolutionally
conserved between yeast and human; and 4) the mutation in codon 295
was identified in tumors of affected patients from the same family with
the loss of the wild-type allele.
So far, screening for germline mutations in hMSH2 and hMLH1
genes has been proposed for members of typical HNPCC families.
In confirmation of several other observations (Mauillon et al.,
1996; Nyström-Lahti et al., 1996; Maslein et al., 1996), we report a
high frequency (44%) of germline mutations of hMLH1 and
hMSH2 in incomplete HNPCC families. The definition of HNPCC
is based on strict clinical criteria, including the identification of
several family members with colon cancer. Combined with the
observation that disease penetrance is incomplete, this often
renders difficult the diagnosis of HNPCC families in small
kindreds. Furthermore, the difficulty of fulfilling all criteria may be
increased by the lack of necessary clinical information. For
instance, in 2 of our 3 incomplete families carrying the hMLH1
gene mutation (FF2 and FF7), for certain first-degree relatives who
died at an early age of a cancer at an unknown site, we were unable
to obtain detailed information. Incomplete HNPCC families repre-
sent a significant fraction of families encountered in genetic
consultations. Consequently, the study of genotype and phenotype
correlation in this group of families should be important for better
selection of families for whom genetic analysis is required.
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FIGURE 4 – Western blot analysis. Proteins (100 µg) from different individuals were separated on a 12.5% SDS-acrylamide electrophoresis gel.
Lanes 1 and 2, unrelated healthy individuals; lanes 3 and 4, HNPCC patients without the hMLH1 mutation; lane 5, patient with the hMLH1
mutation at the initiation codon; lane 6, patient with missense mutation at codon 182; lane 7, patient with nonsense mutation at codon 297; lane 8,
patient with missense mutation at codon 295. Two blots were hybridized with N-terminus polyclonal antibody (a) and C-terminus polyclonal
antibodies (b), respectively. The size for full-length hMLH1 protein is indicated.
835MMR GENE GERMLINE MUTATIONS
REFERENCES
CHARBONNIER, F., MARTIN, C., SCOTTE, M., SIBERT, L., MOREAU, V. and
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NYSTRÖM-LAHTI, M., DE LA CHAPELLE, A. and AALTONEN, L.A., Loss of the
wild type MLH1 gene is a feature of hereditary nonpolyposis colorectal
cancer. Nature (Genet), 8, 405–410 (1994).
KOLODNER, R.D., and 12 OTHERS, Structure of the human MSH2 locus and
analysis of two Muir-Torre kindreds for msh2 mutations. Genomics, 2,
516–526 (1994).
KOLODNER, R.D., HALL, N.R., LIPFORD, J., KANE, M.F., MORRISON, P.T.,
FINAN, P.J., BURN, J., CHAPMAN, P., EARABINO, C., MERCHANT, E. and
BISHOP, D.T., Structure of the human MLH1 locus and analysis of a large
hereditary nonpolyposis colorectal carcinoma kindred for mlh1 mutations.
Cancer Res., 55, 242–248 (1995).
LALLE, P., MOYRET-LALLE, C., WANG, Q., VIALLE, J.M., NAVARRO, C.,
BRESSAC DE PAILLERETS, B., MAGAUD, J.P. and OZTURK, M., Genomic
stability and wild-type p53 function of lymphoblastoı̈d cells with germ-line
p53 mutation. Oncogene, 10, 2447–2454 (1995).
LEACH, F.S., POLYAK, K., BURRELL, M., JOHNSON, K.A., HILL, D., DUNLOP,
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JÖLD, M. and LINDBLOM, A., Mutation screening in the hMLH1 gene in
Swedish hereditary nonpolyposis colon cancer families. Cancer Res., 55,
6092–6096 (1995).
836 WANG ET AL.
